Advanced Cell Technology has filed an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to initiate a Phase I/II multicenter study using embryonic-stem-cell-derived retinal cells to treat patients with Stargardt?s Macular Dystrophy (SMD).
Advanced Cell Technology has filed an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to initiate a Phase I/II multicenter study using embryonic-stem-cell-derived retinal cells to treat patients with Stargardt’s Macular Dystrophy (SMD). Degenerative retinal diseases are among the most common causes of untreatable blindness in the world and while Age-Related Macular Degeneration is the most common of these diseases, SMD is still one of the most common forms of juvenile macular blindness.
“Our research clearly shows that stem-cell-derived retinal cells can rescue visual function in animals that otherwise would have gone blind. We are hopeful that the cells will be similarly efficacious in patients,” said Dr Robert Lanza, ACT’s Chief Scientific Officer.
This treatment uses stem cells to re-create cells in the retina that support the photoreceptors. These cells, called retinal pigment epithelium, are often the first to die off in SMD and AMD, which in turn leads to loss of vision.
AAO 2024: Detail outlined for Artificial Intelligence Innovation Center at Wilmer Eye Institute
October 24th 2024During a conversation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Liu, MD, discussed plans for the James P. Gills Jr, MD, & Heather Gills Artificial Intelligence Innovation Center at the Wilmer Eye Institute at Johns Hopkins Medicine.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.